[go: up one dir, main page]

MX376436B - Derivados de pirazolo-pirimidina terapeuticamente activos. - Google Patents

Derivados de pirazolo-pirimidina terapeuticamente activos.

Info

Publication number
MX376436B
MX376436B MX2015007774A MX2015007774A MX376436B MX 376436 B MX376436 B MX 376436B MX 2015007774 A MX2015007774 A MX 2015007774A MX 2015007774 A MX2015007774 A MX 2015007774A MX 376436 B MX376436 B MX 376436B
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
therapeuticly
pyrazolo
active pyrazolo
active
Prior art date
Application number
MX2015007774A
Other languages
English (en)
Other versions
MX2015007774A (es
Inventor
Anant Ramrao Ghawalkar
Bart Vanderhoydonck
Daniel James Ford
Helen Tracey Horsley
James Thomas Reuberson
Qiuya Huang
Richard Jeremy Franklin
Original Assignee
Ucb Biopharma Sprl
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376436(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1223021.5A external-priority patent/GB201223021D0/en
Priority claimed from GBGB1301935.1A external-priority patent/GB201301935D0/en
Application filed by Ucb Biopharma Sprl, Univ Leuven Kath filed Critical Ucb Biopharma Sprl
Publication of MX2015007774A publication Critical patent/MX2015007774A/es
Publication of MX376436B publication Critical patent/MX376436B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una serie de derivados de pirazolo [3,4-d] pirimidina que son sustituidos en la posición 4- por una porción diaza monocíclica, bicíclica puenteada o espirocíclica, son benéficos en el tratamiento y/o prevención de varias enfermedades humanas, que incluyen trastornos inflamatorios, autoinmunes y oncológicos; enfermedades virales y malaria; y rechazo al transplante de células y órganos.
MX2015007774A 2012-12-20 2013-12-20 Derivados de pirazolo-pirimidina terapeuticamente activos. MX376436B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223021.5A GB201223021D0 (en) 2012-12-20 2012-12-20 Therapeutic agents
GBGB1301935.1A GB201301935D0 (en) 2013-02-04 2013-02-04 Therapeutic agents
PCT/EP2013/077846 WO2014096423A1 (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives

Publications (2)

Publication Number Publication Date
MX2015007774A MX2015007774A (es) 2015-09-04
MX376436B true MX376436B (es) 2025-03-07

Family

ID=49886937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007774A MX376436B (es) 2012-12-20 2013-12-20 Derivados de pirazolo-pirimidina terapeuticamente activos.

Country Status (32)

Country Link
US (1) US9714248B2 (es)
EP (1) EP2935269B1 (es)
JP (1) JP6298830B2 (es)
KR (1) KR102215490B1 (es)
CN (1) CN105008360B (es)
AP (1) AP2015008552A0 (es)
AU (1) AU2013366480B2 (es)
BR (1) BR112015014869A2 (es)
CA (1) CA2893704C (es)
CL (1) CL2015001752A1 (es)
CR (1) CR20150379A (es)
CY (1) CY1120415T1 (es)
DK (1) DK2935269T3 (es)
EA (1) EA027752B1 (es)
ES (1) ES2676515T3 (es)
HR (1) HRP20181008T1 (es)
HU (1) HUE038310T2 (es)
IL (1) IL239163B (es)
LT (1) LT2935269T (es)
MX (1) MX376436B (es)
MY (1) MY189182A (es)
NZ (1) NZ709360A (es)
PE (1) PE20151767A1 (es)
PH (1) PH12015501222A1 (es)
PL (1) PL2935269T3 (es)
PT (1) PT2935269T (es)
SA (1) SA515360627B1 (es)
SG (2) SG11201504291SA (es)
SI (1) SI2935269T1 (es)
TN (1) TN2015000285A1 (es)
TR (1) TR201809140T4 (es)
WO (1) WO2014096423A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
SG11201908691PA (en) 2017-03-20 2019-10-30 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
CN109721531B (zh) * 2017-10-27 2022-07-29 中国科学院合肥物质科学研究院 一种新型的脂质体激酶抑制剂
TWI795510B (zh) 2018-01-17 2023-03-11 英商葛蘭素史密斯克藍智慧財產發展有限公司 PI4KIIIβ抑制劑
MY200452A (en) 2018-08-21 2023-12-27 Kyorin Seiyaku Kk Bicyclic heteroaromatic ring derivative
EP4161518A4 (en) * 2020-06-08 2024-05-29 University of Vermont and State Agricultural College PIPERAZINE ARYLACETAMIDE ANALOGS-[1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES
KR102673131B1 (ko) * 2020-07-28 2024-06-10 아주대학교산학협력단 신규한 톨-유사 수용체 3/7/9 억제 소분자 화합물
WO2024168106A2 (en) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulators of trpml, their compositions and methods of use
WO2024168104A2 (en) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulators of trpml, their compositions and methods of use
CN116444485B (zh) * 2023-03-30 2024-01-23 广西中医药大学 吡啶基取代不对称脲的非金属催化、免柱层析合成方法
WO2024211249A2 (en) * 2023-04-05 2024-10-10 Caraway Therapeutics, Inc. Modulators of trpml, their compositions and methods of use
WO2024249604A2 (en) * 2023-06-02 2024-12-05 Purdue Research Foundation Covalent inhibitors as anti-malarial agents
EP4623911A1 (en) * 2024-03-25 2025-10-01 ETH Zurich Pi4kb inhibitors for the treatment of fatty liver disease
EP4623912A1 (en) 2024-03-25 2025-10-01 ETH Zurich A method for defattening a steatotic liver ex vivo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1110649B (de) * 1957-11-22 1961-07-13 Ciba Geigy Verfahren zur Herstellung von 1-Isopropyl-pyrazolo[3, 4-d]pyrimidinen
ES2356886T3 (es) * 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
US6815444B2 (en) * 2002-05-24 2004-11-09 National Health Research Institutes Anti-enterovirus compounds
WO2005020897A2 (en) * 2003-08-22 2005-03-10 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
WO2006009245A1 (ja) * 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. 含窒素縮合二環式化合物
ATE543821T1 (de) * 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
WO2009097446A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines

Also Published As

Publication number Publication date
TR201809140T4 (tr) 2018-07-23
HK1215705A1 (en) 2016-09-09
EP2935269B1 (en) 2018-04-11
SA515360627B1 (ar) 2018-05-31
PH12015501222B1 (en) 2015-08-17
PL2935269T3 (pl) 2018-09-28
LT2935269T (lt) 2018-07-10
CA2893704A1 (en) 2014-06-26
BR112015014869A2 (pt) 2017-07-11
TN2015000285A1 (en) 2016-10-03
CA2893704C (en) 2020-12-15
EA027752B1 (ru) 2017-08-31
KR20150111348A (ko) 2015-10-05
ES2676515T3 (es) 2018-07-20
US20160194329A1 (en) 2016-07-07
DK2935269T3 (en) 2018-07-16
EP2935269A1 (en) 2015-10-28
KR102215490B1 (ko) 2021-02-15
NZ709360A (en) 2020-01-31
SG10201703094UA (en) 2017-06-29
US9714248B2 (en) 2017-07-25
CN105008360A (zh) 2015-10-28
PT2935269T (pt) 2018-07-16
PE20151767A1 (es) 2015-12-11
AU2013366480B2 (en) 2017-06-22
JP2016503049A (ja) 2016-02-01
IL239163A0 (en) 2015-07-30
AU2013366480A1 (en) 2015-07-09
MY189182A (en) 2022-01-31
PH12015501222A1 (en) 2015-08-17
CY1120415T1 (el) 2019-07-10
CL2015001752A1 (es) 2016-06-03
IL239163B (en) 2018-06-28
WO2014096423A1 (en) 2014-06-26
HUE038310T2 (hu) 2018-10-29
JP6298830B2 (ja) 2018-03-20
SI2935269T1 (sl) 2018-09-28
MX2015007774A (es) 2015-09-04
SG11201504291SA (en) 2015-07-30
HRP20181008T1 (hr) 2018-08-24
EA201500654A1 (ru) 2015-12-30
AP2015008552A0 (en) 2015-06-30
CR20150379A (es) 2015-10-08
CN105008360B (zh) 2017-09-19

Similar Documents

Publication Publication Date Title
MX376436B (es) Derivados de pirazolo-pirimidina terapeuticamente activos.
WO2013024291A3 (en) Therapeutically active fused pyrimidine derivatives
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
EP2751112A4 (en) SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE AND ITS USE
IN2015DN03751A (es)
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA201690303A1 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ
DK3215511T3 (da) Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
CO6791616A2 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a
MX2019003649A (es) Inhibidores selectivos de jak1 novedosos y usos de los mismos.
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
UY34018A (es) Derivados glucósidos y usos de los mismos
WO2014205354A3 (en) Free base crystals
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
DK3596080T3 (da) Farmakologisk aktive alicyclisk-substitueret pyrazolo[1,5-a]pyrimidin-derivater
CR20160155A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
EA201891349A1 (ru) Производные гексагидропиразинотриазинона в качестве ингибиторов киназы
EA201890826A1 (ru) Конденсированные производные пиридина в качестве ингибиторов киназы
UA114825C2 (uk) Терапевтично активні похідні піразолопіримідину
ECSP15031293A (es) Derivados de pirazolo-pirimidina terapeuticamente activos
IL231934A (en) 4-Amino-3-Phenylamino-6-Phenylpyrazolo (4,3-d) Pyramidine derivatives, their production and use as active antiviral substances

Legal Events

Date Code Title Description
FG Grant or registration